Testing midostaurin plus gemtuzumab for newly diagnosed AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies whether combining two medicines—midostaurin and gemtuzumab (with standard chemotherapy)—can improve outcomes for newly diagnosed acute myeloid leukemia (AML). It is testing a first-line treatment plan tailored to specific genetic changes in the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed AML (not a relapse) and you can give informed consent
- Your AML must match specific lab genetic/molecular patterns (some FLT3 or specific chromosome changes)
- Age 18–75 for the first part, or up to 70 for other parts, depending on which module you match
- Your general health is good enough (ECOG 0–2) and you expect to live more than 14 days
- Your liver and kidney tests, plus blood counts, must be within allowed limits (temporary emergency “bridge” treatment may be allowed for short-term stabilization)
- You have not had certain prior treatments (especially prior FLT3 inhibitors or prior anthracycline chemotherapy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called revumenib combined with a strong chemotherapy regimen (7+3) and midostaurin for people with newly diagnosed AML that has specific gene mutations (FLT3 and NPM1). The goal is to see if this combination works better than standard treatments.
This Phase 3 trial tests whether adding gemtuzumab to standard chemotherapy helps people with newly diagnosed, favorable-intermediate AML reduce “MRD” (very small remaining leukemia cells). If MRD levels drop more, it may lower the chance of relapse.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
This study tests a new drug called BL-M11D1 combined with standard chemotherapy (cytarabine + daunorubicin) or a targeted therapy (venetoclax + azacitidine) for people with newly diagnosed acute myeloid leukemia (AML). It aims to see if this combination is safe and effective.
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.